-
公开(公告)号:US06747023B1
公开(公告)日:2004-06-08
申请号:US09762888
申请日:2001-02-12
申请人: Syozo Kobayashi , Satoshi Komoriya , Noriyasu Haginoya , Masanori Suzuki , Toshiharu Yoshino , Takayasu Nagahara , Tsutomu Nagata , Haruhiko Horino , Masayuki Ito , Akiyoshi Mochizuki
发明人: Syozo Kobayashi , Satoshi Komoriya , Noriyasu Haginoya , Masanori Suzuki , Toshiharu Yoshino , Takayasu Nagahara , Tsutomu Nagata , Haruhiko Horino , Masayuki Ito , Akiyoshi Mochizuki
IPC分类号: C07D51304
CPC分类号: C07D207/08 , C07D207/12 , C07D207/22 , C07D211/34 , C07D211/70 , C07D213/56 , C07D213/61 , C07D213/73 , C07D213/75 , C07D213/82 , C07D213/84 , C07D213/89 , C07D233/18 , C07D233/64 , C07D233/88 , C07D239/42 , C07D239/48 , C07D243/08 , C07D277/40 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q1—Q2—T1—Q3—SO2—QA (I) [wherein Q1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C1-6 alkylene group or the like; QA represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.
摘要翻译: 在本发明中描述的是由下式(I)表示的磺酰基衍生物:其中Q 1表示饱和或不饱和的5或6元环烃基,5或6元杂环基,双环稠合 可以具有取代基的环或三环稠环; Q 2表示单键,氧原子,硫原子,直链或支链C 1-6亚烷基等; Q表示芳基烯基 其可以具有取代基或可以具有取代基的杂芳基烯基; 和T 1表示羰基等]和包含该羰基的药物。 该化合物具有强的FXa抑制作用,在口服给药时提供及时,充足和持久的抗血栓作用,副作用小,因此可用作优异的抗凝血剂。
-
公开(公告)号:US06525042B1
公开(公告)日:2003-02-25
申请号:US09508680
申请日:2000-03-28
申请人: Syozo Kobayashi , Satoshi Komoriya , Masayuki Ito , Tsutomu Nagata , Akiyoshi Mochizuki , Noriyasu Haginoya , Takayasu Nagahara , Haruhiko Horino
发明人: Syozo Kobayashi , Satoshi Komoriya , Masayuki Ito , Tsutomu Nagata , Akiyoshi Mochizuki , Noriyasu Haginoya , Takayasu Nagahara , Haruhiko Horino
IPC分类号: C07D24302
CPC分类号: C07D207/08 , C07C2601/14 , C07D207/12 , C07D207/22 , C07D207/38 , C07D211/34 , C07D211/70 , C07D213/26 , C07D213/73 , C07D213/74 , C07D213/82 , C07D213/89 , C07D215/48 , C07D217/02 , C07D233/64 , C07D235/06 , C07D239/42 , C07D239/48 , C07D277/40 , C07D295/26 , C07D307/84 , C07D333/68 , C07D401/10 , C07D401/12 , C07D405/04 , C07D409/04 , C07D495/04 , C07D513/04
摘要: Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1 is hydrogen, hydroxyl, nitro or the like; R2 and R3 are each independently hydrogen, halogeno or the like; R4 and R5 are each dependently hydrogen, halogeno or the like; Q1 is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2 is a single bond, oxygen or the like; Q3 is, e.g., a group represented by formula (a): T1 is carbonyl or the like; and X1 and X2 are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.
摘要翻译: 由通式(I)表示的磺酰基衍生物,它们的盐和两者的溶剂合物:和它们作为药物的应用:[其中R1是氢,羟基,硝基等; R2和R3各自独立地为氢,卤代等; R4和R5各自为氢,卤代等; Q1是任选取代的饱和或不饱和的5-或6-元环烃基等; Q2是单键,氧等; Q3是例如由式(a)表示的基团:T1是羰基等; X1和X2各自独立地是亚甲基或氮]。 这些化合物显示出有力的Fxa抑制活性,并且作为优异的抗凝血剂,其通过口服给药快速发挥令人满意且持久的抗血栓形成作用,并且几乎不引起不良反应。
-
公开(公告)号:US5866577A
公开(公告)日:1999-02-02
申请号:US924504
申请日:1997-09-05
IPC分类号: A61K31/155 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/33 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/451 , A61K31/495 , A61K31/50 , A61K31/505 , A61P7/02 , A61P43/00 , C07C255/52 , C07C255/54 , C07C255/56 , C07C255/58 , C07C257/18 , C07C323/31 , C07C323/32 , C07D207/09 , C07D207/12 , C07D209/04 , C07D211/22 , C07D211/44 , C07D211/46 , C07D239/02 , C07D239/20 , C07D241/02 , C07D307/78 , C07D307/79 , C07D307/80 , C07D307/84 , C07D333/60 , C07D333/68 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D409/10 , C07D409/12 , C07D417/12 , C07D521/00
CPC分类号: C07D307/79 , C07C257/18 , C07D207/12 , C07D211/22 , C07D211/46 , C07D231/12 , C07D233/56 , C07D249/08 , C07D307/80 , C07D307/81 , C07D333/60 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要: An anticoagulant agent which comprises, as an active ingredient, an aromatic amidine derivative represented by the following general formula (1) or a salt thereof: ##STR1## wherein the group represented by ##STR2## is a group selected from indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl; X is a single bond, an oxygen atom, a sulfur atom or a carbonyl group; and Y is a saturated or unsaturated 5- or 6-membered heterocyclic moiety or cyclic hydrocarbon moiety optionally having a substituent group, an amino group optionally having a substituent group or an aminoalkyl group optionally having a substituent group.The inventive compound has a high anticoagulant capacity based on its excellent FXa inhibition activity.
摘要翻译: 作为活性成分,含有下述通式(1)表示的芳香族脒衍生物或其盐的抗凝血剂:其中,由“IMAGE”表示的基团是选自吲哚基, 苯并呋喃基,苯并噻吩基,苯并咪唑基,苯并恶唑基,苯并噻唑基,萘基,四氢萘基和茚满基; X是单键,氧原子,硫原子或羰基; Y是任选具有取代基的任选具有取代基的氨基或任选具有取代基的氨基烷基的饱和或不饱和的5-或6-元杂环部分或环烃部分。 基于其优异的FXa抑制活性,本发明化合物具有高抗凝血能力。
-
公开(公告)号:US5576343A
公开(公告)日:1996-11-19
申请号:US468304
申请日:1995-06-06
IPC分类号: A61K31/155 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/33 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/451 , A61K31/495 , A61K31/50 , A61K31/505 , A61P7/02 , A61P43/00 , C07C255/52 , C07C255/54 , C07C255/56 , C07C255/58 , C07C257/18 , C07C323/31 , C07C323/32 , C07D207/09 , C07D207/12 , C07D209/04 , C07D211/22 , C07D211/44 , C07D211/46 , C07D239/02 , C07D239/20 , C07D241/02 , C07D307/78 , C07D307/79 , C07D307/80 , C07D307/84 , C07D333/60 , C07D333/68 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D409/10 , C07D409/12 , C07D417/12 , C07D521/00
CPC分类号: C07D307/79 , C07C257/18 , C07D207/12 , C07D211/22 , C07D211/46 , C07D231/12 , C07D233/56 , C07D249/08 , C07D307/80 , C07D307/81 , C07D333/60 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要: An anticoagulant agent which comprises, as an active ingredient, an aromatic amidine derivative represented by the following general formula (1) or a salt thereof: ##STR1## wherein the group represented by ##STR2## is a group selected from indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl; X is a single bond, an oxygen atom, a sulfur atom or a carbonyl group; and Y is a saturated or unsaturated 5- or 6-membered heterocyclic moiety or cyclic hydrocarbon moiety optionally having a substituent group, an amino group optionally having a substituent group or an aminoalkyl group optionally having a substituent group.The inventive compound has a high anticoagulant capacity based on its excellent FXa inhibition activity.
-
公开(公告)号:US5962695A
公开(公告)日:1999-10-05
申请号:US131235
申请日:1998-08-07
IPC分类号: A61K31/155 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/33 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/451 , A61K31/495 , A61K31/50 , A61K31/505 , A61P7/02 , A61P43/00 , C07C255/52 , C07C255/54 , C07C255/56 , C07C255/58 , C07C257/18 , C07C323/31 , C07C323/32 , C07D207/09 , C07D207/12 , C07D209/04 , C07D211/22 , C07D211/44 , C07D211/46 , C07D239/02 , C07D239/20 , C07D241/02 , C07D307/78 , C07D307/79 , C07D307/80 , C07D307/84 , C07D333/60 , C07D333/68 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D409/10 , C07D409/12 , C07D417/12 , C07D521/00
CPC分类号: C07D307/79 , C07C257/18 , C07D207/12 , C07D211/22 , C07D211/46 , C07D231/12 , C07D233/56 , C07D249/08 , C07D307/80 , C07D307/81 , C07D333/60 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要: An anticoagulant agent which comprises, as an active ingredient, an aromatic amidine derivative represented by the following general formula (1) or a salt thereof: ##STR1## wherein the group represented by ##STR2## is a group selected from indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl; X is a single bond, an oxygen atom, a sulfur atom or a carbonyl group; and Y is a saturated or unsaturated 5- or 6-membered heterocyclic moiety or cyclic hydrocarbon moiety optionally having a substituent group, an amino group optionally having a substituent group or an aminoalkyl group optionally having a substituent group.The inventive compound has a high anticoagulant capacity based on its excellent FXa inhibition activity.
摘要翻译: 作为活性成分,含有下述通式(1)所示的芳香族脒衍生物或其盐的抗凝血剂,其特征在于,所述基团为选自吲哚基,苯并呋喃基,苯并噻吩基,苯并咪唑基,苯并恶唑基,苯并噻唑基 ,萘基,四氢萘基和茚满基; X是单键,氧原子,硫原子或羰基; Y是任选具有取代基的任选具有取代基的氨基或任选具有取代基的氨基烷基的饱和或不饱和的5-或6-元杂环部分或环烃部分。 基于其优异的FXa抑制活性,本发明化合物具有高抗凝血能力。
-
公开(公告)号:US5620991A
公开(公告)日:1997-04-15
申请号:US471173
申请日:1995-06-06
IPC分类号: A61K31/155 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/33 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/451 , A61K31/495 , A61K31/50 , A61K31/505 , A61P7/02 , A61P43/00 , C07C255/52 , C07C255/54 , C07C255/56 , C07C255/58 , C07C257/18 , C07C323/31 , C07C323/32 , C07D207/09 , C07D207/12 , C07D209/04 , C07D211/22 , C07D211/44 , C07D211/46 , C07D239/02 , C07D239/20 , C07D241/02 , C07D307/78 , C07D307/79 , C07D307/80 , C07D307/84 , C07D333/60 , C07D333/68 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D409/10 , C07D409/12 , C07D417/12 , C07D521/00 , C07D211/06
CPC分类号: C07D307/79 , C07C257/18 , C07D207/12 , C07D211/22 , C07D211/46 , C07D231/12 , C07D233/56 , C07D249/08 , C07D307/80 , C07D307/81 , C07D333/60 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要: An anticoagulant agent which comprises, as an active ingredient, an aromatic amidine derivative represented by the following general formula (1) or a salt thereof: ##STR1## wherein the group represented by ##STR2## is a group selected from indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl; X is a single bond, an oxygen atom, a sulfur atom or a carbonyl group; and Y is a saturated or unsaturated 5- or 6-membered heterocyclic moiety or cyclic hydrocarbon moiety optionally having a substituent group, an amino group optionally having a substituent group or an aminoalkyl group optionally having a substituent group.The inventive compound has a high anticoagulant capacity based on its excellent FXa inhibition activity.
摘要翻译: 作为活性成分,含有下述通式(1)表示的芳香族脒衍生物或其盐的抗凝血剂:其中,由“IMAGE”表示的基团是选自吲哚基, 苯并呋喃基,苯并噻吩基,苯并咪唑基,苯并恶唑基,苯并噻唑基,萘基,四氢萘基和茚满基; X是单键,氧原子,硫原子或羰基; Y是任选具有取代基的任选具有取代基的氨基或任选具有取代基的氨基烷基的饱和或不饱和的5-或6-元杂环部分或环烃部分。 基于其优异的FXa抑制活性,本发明化合物具有高抗凝血能力。
-
-
-
-
-